Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Net Cash Flow: 2020-2024

Historic Net Cash Flow for ARS Pharmaceuticals (SPRY) over the last 5 years, with Dec 2024 value amounting to -$20.2 million.

  • ARS Pharmaceuticals' Net Cash Flow rose 164.50% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.9 million, marking a year-over-year increase of 195.33%. This contributed to the annual value of -$20.2 million for FY2024, which is 85.56% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Net Cash Flow of -$20.2 million as of FY2024, which was up 85.56% from -$139.5 million recorded in FY2023.
  • In the past 5 years, ARS Pharmaceuticals' Net Cash Flow registered a high of $376.4 million during FY2020, and its lowest value of -$139.5 million during FY2023.
  • In the last 3 years, ARS Pharmaceuticals' Net Cash Flow had a median value of -$20.2 million in 2024 and averaged -$3.1 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first skyrocketed by 323.32% in 2022, then slumped by 192.75% in 2023.
  • ARS Pharmaceuticals' Net Cash Flow (Yearly) stood at $376.4 million in 2020, then crashed by 90.56% to $35.5 million in 2021, then skyrocketed by 323.32% to $150.5 million in 2022, then slumped by 192.75% to -$139.5 million in 2023, then soared by 85.56% to -$20.2 million in 2024.